Safety outcomes of darolutamide vs apalutamide and enzalutamide in nmCRPC
Neal Shore, MD, Carolina Urologic Research Center, Myrtle Beach, SC, discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) using matching-adjusted indirect comparisons. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
▶︎
Abiraterone, Enzalutamide, Darolutamide, and Apalutamide: How Oncologists Decide
▶︎
Lupron vs Eligard, Trelstar and Others | #MarkScholzMD #AlexScholz #PCRI
▶︎
Comparing Apalutamide and Enzalutamide in Real-World Treatment of mCSPC
▶︎
Self Advocate and Do Your Own Research | Howard Wolinsky’s #ProstateCancer Patient Story | PCRI
▶︎
Apalutamide vs Enzalutamide: Insights on Real-World Survival Benefits and Clinical Implications
▶︎
Recurrent Prostate Cancer,Rising PSA, Apalutamide,Abiraterone Acetate,Lupron,Degarelix,Enzalutamide
▶︎
New Prescribing Information on Survival Benefit for Nubeqa® (Darolutamide) Approved
▶︎
Prostate Cancer: What You NEED To Know
▶︎
Exclusive interview on ARANOTE study: PSA response with darolutamide plus ADT in patients with mHSPC
▶︎
New FDA Approved PARP Inhibitor: Talzenna (Talazoparib) & Xtandi | #markscholzmd #AlexScholz #pcri
▶︎
Radical prostatectomy vs radiation therapy
▶︎
New FDA Approval: Darolutamide for Hormone-Sensitive Disease | Mark Scholz, MD | PCRI
▶︎
Which Androgen Receptor Pathway Inhibitors (ARPI) to Pick for Treatment of Prostate Cancer
▶︎
Nubeqa (Darolutamide), a Hormone Therapy | Ask a Prostate Expert, Mark Scholz, MD
▶︎
Enzalutamide Approved for Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MD
▶︎
Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
▶︎
#ProstateCancer: Cure vs Remission After Treatment | #markscholzmd | #pcri
▶︎
Live long and PROSPER: enzalutamide for nmCRPC
▶︎
Apalutamide, ADT Improve Outcomes in High-Risk Prostate Cancer Post-Surgery
▶︎